2076975 2077203
최종편집 2024-06-18 17:24 (화)
Pfizer effect, 29.3% average sales growth rate of multinational pharmaceutical companies 
상태바
Pfizer effect, 29.3% average sales growth rate of multinational pharmaceutical companies 
  • Hyeokgi Lee, Newsmp
  • 승인 2022.04.19 10:29
  • 댓글 0
이 기사를 공유합니다

 Combined sales of 33 companies KRW 6.2018 trillion → KRW 8.186 trillion… Operating profit     soared by 51.2% and net profit by 82.1%
 Excluding PfizerㆍOrganonㆍJanssen Vaccine, sales growth rate stood at 5.2%... Operating     Profitㆍnet profit ↑double digits

[Newsmp] Last year, Pfizer Pharmaceutical Korea recorded sales growth of more than 300% with the COVID-19 vaccine, and the average sales growth rate of multinational pharmaceutical companies was close to the 30% mark.

Newsmp tallied the income statements of multinational companies’ subsidiaries in Korea, whose closing accounts are between September and December and submitted audit reports by the 12th, and found that combined sales of 33 companies jumped 29.3% from KRW 6.2018 trillion to KRW 8.186 trillion.

Pfizer Pharmaceutical Korea saw its sales surge 332.3% from KRW 391.9 billion in 2020 to KRW 1.694 trillion due to the effect of the COVID-19 vaccine.

Organon Korea, which was spun off from MSD, reported sales of KRW 218.2 billion in the first year of the spin-off, while Janssen Vaccine, which achieved sales of KRW 5.1 billion in 2020, did not generate sales last year.

Except for the three companies whose sales have changed significantly due to special circumstances, the combined sales of the remaining 30 companies increased 5.2% from KRW 5.8049 trillion to KRW 6.1064 trillion, below the sales growth rate of domestic companies (6.3% based on the listed companies).

The combined operating profit of 33 companies, including Pfizer, Organon, and Janssen Vaccine, jumped 51.2% from KRW 191 billion to KRW 288.7 billion, and net profit surged 82.1% from KRW 196 billion to KRW 356.9 billion.

Excluding the three companies, operating profit rose 12.7% from KRW 224.9 billion to KRW 253.4 billion, and net profit increased 16.3% from KRW 244.7 billion to KRW 284.4 billion, contrary to domestic companies, whose operating and net profit fell by 16 to 17% during the same period.

In terms of sales by company, Pfizer Pharmaceutical Korea took the lead with sales of KRW 1.69 trillion, a 332.3% increase, and was the only company to record more than KRW 1 trillion in sales, followed by AstraZeneca Korea with 31.6% growth to KRW 655.3 billion, exceeding KRW 600 billion.

Novartis Korea increased by 2.3% to KRW 544.2 billion, MSD Korea by 11.8% to KRW 541.9 billion, and Sanofi-Aventis by 8.1% to KRW 530.1 billion, the top five companies achieving more than KRW 500 billion in sales.

Viatris Korea recorded KRW 393.5 billion, Roche Korea KRW 343.9 billion, Bayer Korea KRW 340.1 billion, and GSK KRW 304.4 billion, recording more than KRW 300 billion in sales.

Following companies with sales above KRW 300 billion, Boehringer Ingelheim Korea achieved sales of KRW 292.4 billion, Alcon Korea KRW 238.4 billion, Organon Korea KRW 218.2 billion, and Korea Otsuka Pharmaceuticals KRW 206.6 billion.

Moreover, BMS Korea reported sales of KRW 189.2 billion, Novo Nordisk KRW 188.9 billion, Lilly Korea KRW 177 billion, AbbVie Korea KRW 140.4 billion, and GSK Consumer Healthcare Korea KRW 133.5 billion.

Sanofi Pasteur and Mundipharma Korea’s sales were at the KRW 80 billion mark, Kyowa Kirin Korea, Allergan Korea, and Fresenius Kabi Korea at the KRW 70 billion mark, Lundbeck Korea, Celgene Korea, Galderma Korea, and Ferring Korea at the KRW 60 billion mark, Menarini Korea, Korea UCB, and Servier Korea at the KRW 50 billion mark, and Guerbet Korea at the KRW 40 billion, and Biogen Korea at the KRW 20 billion mark.

Compared to 2020, Pfizer Pharmaceutical Korea had the largest growth rate of 332.3%, followed by AstraZeneca Korea with 31.6% and Allergan Korea with 24.1%, and Alcon Korea, Galderma Korea, BMS Korea, Sanofi Pasteur, Celgene Korea, MSD Korea, and Novo Nordisk recorded double-digit growth rate.

Korea Otsuka Pharmaceuticals, Biogen Korea, Ferring Korea, Lilly Korea, Sanofi-Aventis, Servier Korea, and Kyowa Kirin Korea achieved sales growth of more than 5.2% on average.
On the other hand, Janssen Vaccine did not generate sales, Roche Korea’s sales plunged 22.5%, and GSK, Boehringer Ingelheim Korea, Menarini Korea, AbbVie Korea, and Mundipharma Korea also showed negative growth. 

In terms of operating profit, Pfizer Pharmaceutical Korea also stood out the most. It shifted from a deficit of KRW 4.2 billion in 2020 to a surplus of KRW 59.2 billion last year.

MSD Korea also turned from a loss of KRW 5.8 billion to a surplus of KRW 58 billion.

Korea Otsuka Pharmaceuticals’ operating profit was slightly lower than 2020, but it was still close to the KRW 40 billion, while AstraZeneca Korea, Sanofi-Aventis, and Viatris Korea also achieved more than KRW 20 billion.

In addition, the operating profit of BMS Korea, Bayer Korea, Lilly Korea, GSK, Boehringer Ingelheim Korea, and GSK Consumer Healthcare Korea also exceed KRW 10 billion.

On the other hand, Roche Korea’s deficit widened significantly from KRW 2 billion to KRW 69.6 billion, and that of Janssen Vaccine expanded from KRW 26.7 billion to KRW 32.6 billion. Of the 33 companies, only two recorded operating losses.

Pfizer Pharmaceutical Korea’s net profit also turned from a loss of KRW 21.2 billion to a massive surplus of KRW 95.9 billion, and MSD Korea’s increased sharply from KRW 100 million to KRW 60.9 billion.

Moreover, the net profit of Novartis Korea surged more than 500% from KRW 7.6 billion to KRW 47.2 billion, while Korea Otsuka Pharmaceuticals maintained a net profit of nearly KRW 30 billion.

Sanofi-Aventis, AstraZeneca Korea, Viatris Korea, BMS Korea, Bayer Korea, GSK, and Novo Nordisk also achieved net profits of more than KRW 10 billion.

However, among them, Bayer Korea’s net profit plummeted from KRW 40 billion to KRW 14.4 billion, and Viatris Korea’s from KRW 22.6 billion to KRW 15.8 billion.

On the contrary, Roche Korea, which had a surplus of KRW 29.7 billion in 2020, reported a deficit of KRW 5.5 billion, and Mundipharma Korea, which had a surplus of KRW 11 billion, recorded a loss of KRW 11.5 billion. Furthermore, Janssen Vaccine’s deficit widened from KRW 27.5 billion to KRW 29.6 billion.
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.